Re: ZEN-3694 mCRPC Trial Status

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

tada

Rank: President [?]

Points: 7656 [?]

Votes: 40 Score: 3.4 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: ZEN-3694 mCRPC Trial Status

in response to

Re: ZEN-3694 mCRPC Trial Status

BearDownAZ

posted on Nov 18, 2017 07:45PM

Thanks Bear.

To be clear, it is only the single agent arm for mCRPC that has been completed. The combination arm is still ongoing and the breast cancer arm has yet to begin.